Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Stomach Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Esophageal Neoplasms 2Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

Sorafenib 52pembrolizumab 26Nivolumab 20Bevacizumab 19Radiosurgery 17Doxorubicin 12atezolizumab 9Erlotinib Hydrochloride 9lenvatinib 8cabozantinib 7Magnetic Resonance Spectroscopy 7tremelimumab 6durvalumab 6Ramucirumab 6Radiofrequency Ablation 6Cisplatin 6Sunitinib 5tislelizumab 4regorafenib 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Everolimus 4Capecitabine 4nintedanib 3fluoromisonidazole 3carotuximab 3bavituximab 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Hepatocellular × Floxuridine × Clear all
NCT00410956 2024-12-10

Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
22 enrolled 12 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡